Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Silence Therapeutics ( (SLN) ).
On 5 March 2026, Silence Therapeutics reported fourth-quarter and full-year 2025 results, highlighting clinical progress across its siRNA pipeline and an updated corporate presentation. The company said enrollment in its Phase 2 SANRECO trial of divesiran for polycythemia vera had been expedited, bringing topline data forward to the third quarter of 2026 and underscoring divesiran as its highest-priority, first-in-class program.
Silence also confirmed its Phase 3–ready Lp(a)-lowering candidate zerlasiran is positioned for partnering, while AstraZeneca shared positive Phase 1 data for dyslipidemia drug SLN312 but opted on 4 March 2026 not to develop it further, returning global rights to Silence. The group reported promising preclinical data for new obesity and cholesterol programs, board-level changes including the December 2025 appointment of Iain Ross as interim principal executive officer, and a sharply wider 2025 net loss of $88.6 million on minimal collaboration revenue, despite flat R&D spend and lower G&A costs.
The most recent analyst rating on (SLN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
The score is primarily held back by weak financial performance (large losses and worsening cash burn), with technicals also leaning soft (below key moving averages and negative MACD). Pipeline progress from the Phase 2 enrollment completion provides a modest offset, while valuation is difficult to support due to negative earnings and no dividend data.
To see Spark’s full report on SLN stock, click here.
More about Silence Therapeutics
Silence Therapeutics plc is a global clinical-stage biotechnology company developing precision-engineered medicines using proprietary siRNA technology. Leveraging its mRNAi GOLD platform, the company is advancing a pipeline of gene-silencing therapies for rare and common diseases with high unmet medical need, including blood disorders, cardiovascular conditions, dyslipidemia, obesity and cholesterol management.
Average Trading Volume: 268,771
Technical Sentiment Signal: Sell
Current Market Cap: $267.6M
See more data about SLN stock on TipRanks’ Stock Analysis page.